Question

Which of the following statements BEST summarizes the evidence supporting the netarsudil/latanoprost fixed-dose combination?

Answer 1

Short answer
Two large randomized, double‑masked phase‑3 trials showed the netarsudil/latanoprost fixed‑dose combination (Rocklatan) produces greater intraocular‑pressure (IOP) lowering than either component alone (statistically superior to latanoprost and netarsudil), with a higher proportion of patients achieving clinically meaningful IOP reductions. The benefit is modest but consistent (roughly an extra ~1–2 mmHg vs latanoprost), and the combination is generally well tolerated systemically but causes more ocular adverse events (conjunctival hyperemia, conjunctival hemorrhage, corneal verticillata) than latanoprost alone. This evidence supported regulatory approval for treatment of open‑angle glaucoma and ocular hypertension.

Key points supporting that summary
- Study design: randomized, double‑masked, multicenter phase‑3 trials comparing the fixed‑dose combo to each monotherapy.
- Efficacy: greater mean diurnal IOP reduction and higher responder rates (e.g., ≥25% IOP reduction) with the fixed combination than with either netarsudil or latanoprost alone.
- Magnitude: clinically meaningful additional lowering but not a dramatic difference—statistically significant, typically on the order of about 1–2 mmHg more than latanoprost.
- Safety/tolerability: more frequent ocular AEs (notably conjunctival hyperemia, conjunctival hemorrhage, corneal verticillata); systemic adverse events are uncommon.
- Rationale: complementary mechanisms (latanoprost increases uveoscleral outflow; netarsudil improves trabecular outflow and lowers episcleral venous pressure) explain additive IOP lowering.

If you want, I can cite the pivotal trial names/publication details or show the specific numerical results from the trials.